IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Abroad (travel likely)RecruitingPHASE2

Conditions

CLDN18.2 Positive · Gastric/Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Tingbo Liang) · liangtingbo_trial@163.com · 0571-87236685
Contact: Study coordinator (Xueli Bai) · liangtingbo_trial@163.com · 0571-87236685
Contact: Principal Investigator (Xueli Bai, PhD)
Contact: Principal Investigator (Tingbo Liang, PhD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

CLDN18.2 Positive · Primary Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Hefei, China · Hefei, China

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Malignant Neoplasms of Digestive Organs

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE3

Hefei, China · Beijing, China